Pain-drug stock in pain itself, falls 40%

July 28, 2014 6:03 PM

36 0

AcelRx Pharmaceuticals (ACRX) is down 40% Monday after the U.S. Food and Drug Administration rejected the company’s pain drug device.

It’s not a death blow to the product, called Zalviso, necessarily. AcelRx told investors it can answer all the FDA’s questions about the product and plans to resubmit for approval by the end of 2014.

Read more

To category page